• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Basic Materials·ASTEC.NS
Share

Astec LifeSciences Limited Stocks

₹ 777.45Last Updated 22.05.2026

Issuer Rating

3/7
Performance

Modest

Risk

Moderate

Recommendation

Sell

Market Cap

₹ 179.71M

₹ 777.45
Key Takeaways

Risk factor

Poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Astec LifeSciences Limited, together with its subsidiaries, manufactures, distributes, and sells agrochemicals active ingredients and pharmaceutical intermediates in India. It manufactures a range of fungicides, insecticides, herbicides, and intermediates, such as triazole fungicides, heterocyclic herbicides, sulfonyl urea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, and silane derivatives; fluorinated aromatic amines, pyridine derivatives, aromatic carboxylic acids, benzyl alcohols, ketones and benzophenones, and heterocyclic mercaptans; fluorinated aromatic, aliphatic, and heterocyclic intermediates; heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, heterocyclic sulfonyl chlorides, heterocyclic sulphonamides, heterocyclic carbamates, thiourium salts, alkyl and aryl chloroformates, substituted pyrimidine diones, and pyrazolones; and substituted 1,2- and 1,3- pyrimidines. The company's products also comprise pyrazolyl aromatic ketones, morpholine derivatives, aromatic azo compounds, substituted triazines, imidate ethers, mesylated intermediates, substituted epoxides, ketals and bromo ketals, aromatic and aliphatic ethers, cyclopropyl ethers, cyclopropyl aldehydes and ketones, conjugated ketones, acetophenone derivatives, pinacolone derivatives, aliphatic and aromatic carboxylic acids, aliphatic and aromatic acid chlorides, halogenated and non-halogenated anhydrides, aliphatic alkenes, and halo alkanes; and aliphatic and aromatic brominated derivatives, cyanides, esters, carboxamides, amines, and alcohols and diols. It also exports its products. The company was incorporated in 1994 and is based in Mumbai, India. Astec LifeSciences Limited is a subsidiary of Godrej Agrovet Limited.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7

The average target price of ASTEC.NS is 776 and suggests 1% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendatio

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

26.05.2026 16:03

Hedge funds make record 10-year bets on tech sector - Goldman Sachs

26.05.2026 15:57

Morning in New York: the situation is favorable for buying

26.05.2026 15:15

A bid for a monopoly in space and a premium for faith: what SpaceX's IPO means for investors

26.05.2026 14:53

Starbucks in Korea has apologized for the scandalous ads. He expects a big drop in sales

26.05.2026 13:10

Ferrari has revealed an electric car with a controversial design from the iPhone's creator. What about the stock

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026